Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 22:8:77.
doi: 10.1186/1475-2875-8-77.

The effect of varying analytical methods on estimates of anti-malarial clinical efficacy

Affiliations

The effect of varying analytical methods on estimates of anti-malarial clinical efficacy

Wendy J Verret et al. Malar J. .

Abstract

Background: Analytical approaches for the interpretation of anti-malarial clinical trials vary considerably. The aim of this study was to quantify the magnitude of the differences between efficacy estimates derived from these approaches and identify the factors underlying these differences.

Methods: Data from studies conducted in Africa and Thailand were compiled and the risk estimates of treatment failure, adjusted and unadjusted by genotyping, were derived by three methods (intention to treat (ITT), modified intention to treat (mITT) and per protocol (PP)) and then compared.

Results: 29 clinical trials (15 from Africa and 14 from Thailand) with a total of 65 treatment arms (38 from Africa and 27 from Thailand) were included in the analysis. Of the 15,409 patients enrolled, 2,637 (17.1%) had incomplete follow up for the unadjusted analysis and 4,489 (33.4%) for the adjusted analysis. Estimates of treatment failure were consistently higher when derived from the ITT or PP analyses compared to the mITT approach. In the unadjusted analyses the median difference between the ITT and mITT estimates was greater in Thai studies (11.4% [range 2.1-31.8]) compared to African Studies (1.8% [range 0-11.7]). In the adjusted analyses the median difference between PP and mITT estimates was 1.7%, but ranged from 0 to 30.9%. The discrepancy between estimates was correlated significantly with the proportion of patients with incomplete follow-up; p < 0.0001. The proportion of studies with a major difference (> 5%) between adjusted PP and mITT was 28% (16/57), with the risk difference greater in African (37% 14/38) compared to Thai studies (11% 2/19). In the African studies, a major difference in the adjusted estimates was significantly more likely in studies in high transmission sites (62% 8/13) compared to studies in moderate transmission sites (24% 6/25); p = 0.035.

Conclusion: Estimates of anti-malarial clinical efficacy vary significantly depending on the analytical methodology from which they are derived. In order to monitor temporal and spatial trends in anti-malarial efficacy, standardized analytical tools need to be applied in a transparent and systematic manner.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between incomplete follow up and the risk difference between unadjusted estimates from ITT and mITT analysis. Closed circles for African studies (38 treatment arms) and open circles for Thai studies (27 treatment arms).
Figure 2
Figure 2
Relationship between incomplete follow up and the risk difference between adjusted estimates from PP and mITT analysis. Closed markers for African studies (38 treatment arms) and open for Thai studies (19 treatment arms). Diamonds = 28 day studies, Circles = 42 days studies and triangles 63 days studies.

Similar articles

Cited by

References

    1. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995–2005. Malar J. 2006;5:122. doi: 10.1186/1475-2875-5-122. - DOI - PMC - PubMed
    1. WHO Guidelines for the treatment of malaria. Document No WHO/HTM/MAL/20061108.
    1. Guthmann JP, Pinoges L, Checchi F, Cousens S, Balkan S, van Herp M, Legros D, Olliaro P. Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. Antimicrob Agents Chemother. 2006;50:3734–3739. doi: 10.1128/AAC.01618-05. - DOI - PMC - PubMed
    1. Borrmann S, Peto T, Snow RW, Gutteridge W, White NJ. Revisiting the dsign of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Med. 2008;5:e227. doi: 10.1371/journal.pmed.0050227. - DOI - PMC - PubMed
    1. Ashley EA, Pinoges L, Turyakira E, Dorsey G, Checchi F, Bukirwa H, Broek I van den, Zongo I, Urruta PP, van Herp M, Balkan S, Taylor WR, Olliaro P, Guthmann JP. Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children. Malar J. 2008;7:154. doi: 10.1186/1475-2875-7-154. - DOI - PMC - PubMed

Publication types

MeSH terms